In an interview with PharmaShots, Tom Corbridge, Senior Medical Lead at GSK shared his views on the approval of its anti-IL-5 biologic NUCALA (mepolizumab) in a 40 mg pre-filled syringe for appropriate children aged 6 to 11 years old with severe eosinophilic asthma (SEA)
Shots:
Nucala can now be given by a child’s HCPs or administered…
In an interview with PharmaShots, Diana Peninger, President and CEO at Reproductive Solutions shares her views on the ProteX sperm collection solution, offering a new hope for infertile couples.
Shots:
Reproductive Solutions (RSI) reported the availability of a patented, FDA-listed semen collection container that improves specimen quality for in vitro fertilization and other assisted reproductive technologies
The ProteX container…
The US FDA has approved 3 NDAs and 2 BLAs in Jan 2022, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 5 novel products in 2022
In Jan 2022, the major highlights were Quviviq's approval for insomnia, Cibinqo for atopic dermatitis, Kimmtrak for unresectable or metastatic…
The US FDA has approved 8 NDAs and 1 BLAs in Dec 2021, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 50 novel products in 2021
In the year 2021, the major highlights were oncology drugs in which 12 out of 50 has approved in oncology,…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients
During the month of November, Bio-Thera Solutions reported the NMPA's acceptance of…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients
During the month of October, Bio-Thera expanded its partnership with Pharmapark to…
The US FDA has approved 5 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry
The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 55 novel products in 2021
Additionally, last year in 2020, the US FDA…
In an interview with PharmaShots, Suela Sulo, Ph.D., M.S., Director of Global Health Economics, Outcomes Research and Policy at Abbott shared her views on how this study will shift the way to approach nutrition across the continuum of care.
Shots:
A study published in the Journal of Primary Care and Community Health has shown that a new…
In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his views on the data of triple combination regimen presented at ASCO and also shed light on the impact of plinabulin on SCLC.
Shots:
Plinabulin in combination with nivolumab and ipilimumab showed 46% ORR with one…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients
During the month of Jun, Celltrion launched Remsima SC (biosimilar, infliximab) for…

